MKGAF
Price
$129.15
Change
+$1.90 (+1.49%)
Updated
Sep 5 closing price
Capitalization
55.52B
OASMY
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
Aug 21 closing price
Capitalization
13.22M
65 days until earnings call
Interact to see
Advertisement

MKGAF vs OASMY

Header iconMKGAF vs OASMY Comparison
Open Charts MKGAF vs OASMYBanner chart's image
Merck KGaA
Price$129.15
Change+$1.90 (+1.49%)
Volume$594
Capitalization55.52B
VIVESTO AB
Price$0.02
Change-$0.00 (-0.00%)
Volume$240
Capitalization13.22M
MKGAF vs OASMY Comparison Chart in %
Loading...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MKGAF vs. OASMY commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MKGAF is a Hold and OASMY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (MKGAF: $129.15 vs. OASMY: $0.02)
Brand notoriety: MKGAF and OASMY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MKGAF: 111% vs. OASMY: 32%
Market capitalization -- MKGAF: $55.52B vs. OASMY: $13.22M
MKGAF [@Pharmaceuticals: Generic] is valued at $55.52B. OASMY’s [@Pharmaceuticals: Generic] market capitalization is $13.22M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MKGAF’s FA Score shows that 1 FA rating(s) are green whileOASMY’s FA Score has 0 green FA rating(s).

  • MKGAF’s FA Score: 1 green, 4 red.
  • OASMY’s FA Score: 0 green, 5 red.
According to our system of comparison, MKGAF is a better buy in the long-term than OASMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MKGAF’s TA Score shows that 3 TA indicator(s) are bullish.

  • MKGAF’s TA Score: 3 bullish, 4 bearish.

Price Growth

MKGAF (@Pharmaceuticals: Generic) experienced а +4.36% price change this week, while OASMY (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

OASMY is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MKGAF($55.5B) has a higher market cap than OASMY($13.2M). MKGAF YTD gains are higher at: -14.786 vs. OASMY (-50.000). MKGAF has higher annual earnings (EBITDA): 5.87B vs. OASMY (-33.93M). MKGAF has more cash in the bank: 1.57B vs. OASMY (4.22M). MKGAF has higher revenues than OASMY: MKGAF (21.2B) vs OASMY (0).
MKGAFOASMYMKGAF / OASMY
Capitalization55.5B13.2M420,455%
EBITDA5.87B-33.93M-17,303%
Gain YTD-14.786-50.00030%
P/E Ratio16.81N/A-
Revenue21.2B0-
Total Cash1.57B4.22M37,266%
Total Debt9.4BN/A-
FUNDAMENTALS RATINGS
MKGAF vs OASMY: Fundamental Ratings
MKGAF
OASMY
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
41
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7096
PRICE GROWTH RATING
1..100
6285
P/E GROWTH RATING
1..100
92100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MKGAF's Valuation (23) in the null industry is in the same range as OASMY (41). This means that MKGAF’s stock grew similarly to OASMY’s over the last 12 months.

MKGAF's Profit vs Risk Rating (100) in the null industry is in the same range as OASMY (100). This means that MKGAF’s stock grew similarly to OASMY’s over the last 12 months.

MKGAF's SMR Rating (70) in the null industry is in the same range as OASMY (96). This means that MKGAF’s stock grew similarly to OASMY’s over the last 12 months.

MKGAF's Price Growth Rating (62) in the null industry is in the same range as OASMY (85). This means that MKGAF’s stock grew similarly to OASMY’s over the last 12 months.

MKGAF's P/E Growth Rating (92) in the null industry is in the same range as OASMY (100). This means that MKGAF’s stock grew similarly to OASMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MKGAFOASMY
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
68%
N/A
Momentum
ODDS (%)
Bearish Trend 3 days ago
67%
N/A
MACD
ODDS (%)
Bullish Trend 3 days ago
65%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 3 days ago
22%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
13%
Advances
ODDS (%)
Bullish Trend 5 days ago
59%
N/A
Declines
ODDS (%)
Bearish Trend 10 days ago
63%
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CISO1.040.16
+18.20%
CISO Global
FOXF29.230.90
+3.18%
Fox Factory Holding Corp
IBN31.67-0.21
-0.66%
ICICI Bank Limited
CHRD103.42-4.06
-3.78%
Chord Energy Corp
FFAI1.81-0.10
-5.24%
Faraday Future Intelligent Electric Inc

OASMY and

Correlation & Price change

A.I.dvisor tells us that OASMY and MVMDF have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OASMY and MVMDF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OASMY
1D Price
Change %
OASMY100%
N/A
MVMDF - OASMY
9%
Poorly correlated
-9.82%
MKGAF - OASMY
4%
Poorly correlated
+1.49%
PCLOF - OASMY
2%
Poorly correlated
+5.13%
OMID - OASMY
2%
Poorly correlated
N/A
OILFF - OASMY
1%
Poorly correlated
-10.49%
More